RYBREVANT® by Johnson & Johnson Revolutionizes NSCLC Treatment
Johnson & Johnson's Phase 3 MARIPOSA study showed promising results for RYBREVANT® (amivantamabvmjw) combined with lazertinib as a first-line treatment for non-small cell lung cancer (NSCLC) patients with EGFR mutations. This combination therapy significantly improved progression-free survival (PFS) compared to osimertinib, particularly in high-risk patient subgroups with EGFR exon 19 deletion (ex19del) or L858R mutations. Presented at the 2024 ASCO Annual Meeting, these findings highlight the potential of RYBREVANT plus lazertinib as a critical first-line option for EGFR-mutated NSCLC patients, addressing important unmet needs. Dr. Byoung Chul Cho, the study author and a medical oncologist at Yonsei Cancer Center, emphasized the significance of these results for improving patient outcomes.
RYBREVANT® by Johnson & Johnson Revolutionizes NSCLC Treatment